GILEAD SCIENCES, INC.

Average Profitability
<0.0001%
Insider Buys Quantity
9
Insider Buys Sum
$613.11M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of GILEAD SCIENCES, INC.

According to the SEC Form 4 filings, GILEAD SCIENCES, INC., being in a position of

  1. 10 percent owner at Assembly Biosciences, Inc.,
    оver the last 12 months, has bought 1119999 shares for $20.1M, and sold 0 shares,
    over all time since 2024-06-17, has bought 1119999 shares for $20.1M, and sold 0 shares.
  2. 10 percent owner at Kyverna Therapeutics, Inc.,
    оver the last 12 months, has bought 910000 shares for $20.02M, and sold 0 shares,
    over all time since 2024-02-12, has bought 910000 shares for $20.02M, and sold 0 shares.
  3. 10 percent owner at Xilio Therapeutics, Inc.,
    оver the last 12 months, has bought 2245228 shares for $2.2M, and sold 0 shares,
    over all time since 2024-04-02, has bought 2245228 shares for $2.2M, and sold 0 shares.

The largest purchase of all time was on 2024-01-29 and amounted to 15238095 shares of Arcus Biosciences, Inc. for $320M.

Biography of GILEAD SCIENCES, INC.

No biography is available at this moment.

2024-12-19PurchaseAssembly Biosciences, Inc.
ASMB
10 percent owner
940,499
20.3736%
$21.37$20.1M-0.95%
2024-12-18PurchaseXilio Therapeutics, Inc.
XLO
10 percent owner
1.76M
4.8987%
$1.04$1.83M-13.46%
2024-06-17PurchaseAssembly Biosciences, Inc.
ASMB
10 percent owner
179,500
0.0002%
$0.00$180+1.45%
2024-04-02PurchaseXilio Therapeutics, Inc.
XLO
10 percent owner
485,250
0.9047%
$0.76$368,790-33.18%
2024-02-12PurchaseKyverna Therapeutics, Inc. Common Stock
KYTX
10 percent owner
910,000
8.0369%
$22.00$20.02M-74.56%
2024-01-29PurchaseArcus Biosciences, Inc.
RCUS
10 percent owner
15.24M
28.0689%
$21.00$320M+6.23%
2023-06-28PurchaseArcus Biosciences, Inc.
RCUS
10 percent owner
1.01M
1.3257%
$19.26$19.45M-15.57%
2023-06-27PurchaseAlloVir, Inc.
ALVR
10 percent owner
2.93M
3.6696%
$3.75$10.99M-74.7%
2021-01-31PurchaseArcus Biosciences, Inc.
RCUS
10 percent owner
5.65M
9.458%
$39.00$220.35M
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.